We’ll help you create
innovative new products

We’re true partners with a proven
commercial record.

TELL ME MORE

We’ll help you create
innovative new products

We’re true partners with a proven commercial record.

TELL ME MORE

Creo’s founders have a history of successful innovation at scale.

TELL ME MORE

The courage
to create
the future

Creo’s founders have a history of successful innovation at scale.

The courage to
create the future

Quality you can trust

By delivering pure cannabinoid ingredients in commercial quantities we’ll help you bring exciting new consumer products to the mass market.

TELL ME MORE

A more sustainable source.

Available at scale.

High quality, consistent and free from contaminants.

Quality you can trust

By delivering pure cannabinoid ingredients in commercial quantities we’ll help you bring exciting new consumer products to the mass market.

TELL ME MORE

A more sustainable source.

Available at scale.

High quality, consistent and free from contaminants.

Quality you can trust

By delivering pure cannabinoid ingredients in commercial quantities we’ll help you bring exciting new consumer products to the mass market.

TELL ME MORE

A more sustainable source.

Available at scale.

High quality, consistent and free from contaminants.

CBG and CBGA
available at scale

CBG and CBGA offer enormous promise.
We’re enabling that promise to become reality.

TELL ME MORE

CBG and CBGA
available at scale

CBG and CBGA offer enormous promise.
We’re enabling that promise to become reality.

TELL ME MORE

CBG and CBGA
available at scale

CBG and CBGA offer enormous promise.
We’re enabling that promise to become reality.

TELL ME MORE

Analyst firm Edison Research ranks Creo as one of the leadings players in the emerging cannabinoid biosynthesis market estimated to be worth some $30bn on an NPV basis.

TELL ME MORE

A wide range of rare cannabinoids available now

You can now order a wide range of high-quality,  rare cannabinoids through our sourcing business, Curated by Creo.

TELL ME MORE

"Analyst firm Edison Research ranks Creo as one of the leadings players in the emerging cannabinoid biosynthesis market estimated to be worth some $30bn on an NPV basis.”